- Home
- BKD vs AGIO Comparison
BKD vs AGIO Comparison
Compare BKD & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKD
- AGIO
- Stock Information
- Founded
- BKD 2005
- AGIO 2007
- Country
- BKD United States
- AGIO United States
- Employees
- BKD N/A
- AGIO N/A
- Industry
- BKD Hospital/Nursing Management
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- BKD Health Care
- AGIO Health Care
- Exchange
- BKD Nasdaq
- AGIO Nasdaq
- Market Cap
- BKD 1.5B
- AGIO 1.4B
- IPO Year
- BKD 2005
- AGIO 2013
- Fundamental
- Price
- BKD $6.85
- AGIO $27.32
- Analyst Decision
- BKD Buy
- AGIO Buy
- Analyst Count
- BKD 5
- AGIO 8
- Target Price
- BKD $7.70
- AGIO $56.00
- AVG Volume (30 Days)
- BKD 3.2M
- AGIO 515.6K
- Earning Date
- BKD 05-06-2025
- AGIO 05-01-2025
- Dividend Yield
- BKD N/A
- AGIO N/A
- EPS Growth
- BKD N/A
- AGIO N/A
- EPS
- BKD N/A
- AGIO 11.45
- Revenue
- BKD $3,015,786,000.00
- AGIO $37,035,000.00
- Revenue This Year
- BKD $8.73
- AGIO $40.62
- Revenue Next Year
- BKD N/A
- AGIO $216.26
- P/E Ratio
- BKD N/A
- AGIO $2.42
- Revenue Growth
- BKD 4.05
- AGIO 25.96
- 52 Week Low
- BKD $4.45
- AGIO $23.42
- 52 Week High
- BKD $8.12
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- BKD 65.68
- AGIO 41.34
- Support Level
- BKD $6.07
- AGIO $27.78
- Resistance Level
- BKD $6.80
- AGIO $31.55
- Average True Range (ATR)
- BKD 0.25
- AGIO 1.38
- MACD
- BKD 0.03
- AGIO -0.03
- Stochastic Oscillator
- BKD 94.52
- AGIO 2.98
About BKD Brookdale Senior Living Inc.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.